Immunogen Stock News

Phase 1 data for its ovarian cancer candidate was a little disappointing.

Is it a good or bad thing when a stock experiences a golden cross technical event?

Is it a good or bad thing when a stock experiences a golden cross technical event?

The biotech company that focuses on oncology drugs released news from a positive clinical trial regarding its lead drug.

The biotech company that focuses on oncology drugs released news from a positive clinical trial regarding its lead drug.

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Webcast of Presentation and Q&A at the 40th Annual J.P. Morgan Healthcare Conference

ImmunoGen: Going Into A Transformative Year

According to the report, The global Next-Generation Antibody Therapeutics market size is expected to reach $ Billion by 2028 growing at the CAGR of 13.4% from 2021 to 2028 The enormous success of monoclonal antibody discovery and development gave an

ImmunoGen, Inc. (NASDAQ:IMGN) saw a significant decline in short interest in the month of November. As of November 30th, there was short interest totalling 8,490,000 shares, a decline of 18.6% from the November 15th total of 10,430,000 shares. Based on an average trading volume of 3,480,000 shares, the short-interest ratio is currently 2.4 days. Currently, []

Today''s Daily Dose brings you news about AstraZeneca''s new long-term data related to cancer drug Calquence; superior efficacy of Novartis'' Scemblix compared to Bosulif in chronic myeloid leukemia; and ImmunoGen''s updated initial safety and efficacy findings from its phase 1b/2 study of IMGN632 in combination with Vidaza and Venclexta in patients with relapsed/refractory acute myeloid leukemia.

They may deliver major gains down the road.

They may deliver major gains down the road.

PALM BEACH, Fla. , Dec. 10, 2021 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - Ongoing advancements in cancer research continue to lead to the introduction of newer and better treatment options including drug therapies. The provision of newer drugs and treatments is expected to improve the diagnostic and treatment rate for triple-negative breast cancer . Some of the recent clinical efforts are being targeted at the molecular level characterization of triple-negative breast cancer across emerging therapeutic targets such as epigenetic proteins, PARP1, androgen receptors, receptor and non-receptor tyrosine kinases, and immune checkpoints. These initiatives are anticipated to boost revenue growth of the triple-negative breast cancer treatment market. In a new research study, Persistence Market Research estimates the global triple-negative breast cancer treatment market revenue to cross US$ 720 Mn by 2026 from an estimated valuation of just under US$ 505 Mn in 2018. This is indicative of a CAGR of 4.7% during the period 2018 to 2026.

The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative development. The sector r